Kanamycin sulfate

Research use only, not for human use.

Kanamycin sulfate is an aminoglycoside bacteriocidal antibiotic.

Kanamycin sulfate is an aminoglycoside bacteriocidal antibiotic.(In Vitro):Kanamycin sulfate (0.1-100 μg/mL; 2 weeks) exhibits good antibacterial activity (MIC=1-5 μg/mL) to various strains of mycobacteria in vitro.(In Vivo):Kanamycin sulfate (2, 4 mg/kg; s.c.; once daily, 6 times a week for 3 weeks) inhibits growth of bovine tubercle bacilli in lung and spleen of mice.Kanamycin sulfate (1.25, 5 mg/kg; s.c.; single (at 3 h after infection)) inhibits the multiplication of K. pneumonia DT-S in lung, trachea, and blood of mice and in proportion to the dose administration, and also increases the survival rate of mice.

Kanamycin sulfate (0.1-100 μg/mL; 2 weeks) exhibits good antibacterial activity (MIC=1-5 μg/mL) to various strains of mycobacteria in vitro. Cell Viability Assay Cell Line:mycobacteria H37Rv, H2, H37RvR-PAS, Ravenel, Kirchbergand and BCG.Concentration:0.1-100 μg/mL Incubation Time:2 weeks Result:Showed good antibacterial activity to various strains of mycobacteria (H37Rv, H2, H37RvR-PAS, Ravenel, and BCG) with MICs were 1 μg/mL and 5 μg/mL for strain of Kirchbergand.

Kanamycin sulfate (2, 4 mg/kg; s.c.; once daily, 6 times a week for 3 weeks) inhibits growth of bovine tubercle bacilli in lung and spleen of mice.Kanamycin sulfate (1.25, 5 mg/kg; s.c.; single (at 3 h after infection)) inhibits the multiplication of K. pneumonia DT-S in lung, trachea, and blood of mice and in proportion to the dose administration, and also increases the survival rate of mice. Animal Model:Inbred strain normal mice (14-16 g; bovine tubercle bacilli (Ravenel strain) infected model).Dosage:2, 4 mg/kg Administration:Subcutaneous injection; once daily, 6 times a week for 3 weeks.Result:Exerted a marked effect to inhibit the multiplication of the tuberculosis in vivo, especially in the lung of mice.Animal Model:Slc:ICR male mice (4-week-old; 18-24 g; K. pneumonia DT-S infection model (by the aerosol method)).Dosage:1.25, 5 mg/kg Administration:Subcutaneous administration; single (at 3 h after infection).Result:Suppressed the growth of K. pneumonia DT-S in lung, trachea, and blood in proportion to the dose administration.Resulted in 90% survival at 6 days after infection (negative control group: all died within 4 days), and cleared the K. pneumonia DT-S from lung, trachea, and blood of mice within 48 h (when dosage at 5 mg/kg).

Ophtalmokalixan

Microbiology/Virology

ribosome

16S ribosome| 30S ribosome

Infection

——

25389-94-0

582.58

C18H38N4O15S

>98% (HPLC)

Water: > 10 mg/mL

C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N.OS(=O)(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years